Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6KI0D)

Drug Name

Repirinast Drug Info

Synonyms

MY-1250; MY-5116; MY-6116

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Approved	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Histamine receptor (HR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Histamine Phosphate	DMV7IM6	Diagnostic imaging	N.A.	Approved	[3]
Levomequitazine	DMAYC76	Seasonal allergic rhinitis	CA08.01	Phase 3	[4]
ETX-9101	DMZOA2L	Asthma	CA23	Phase 2	[5]
LCB-2183	DMY4IWC	Asthma	CA23	Phase 2	[6]
ETS-6218	DMV96BY	Fibromyalgia	MG30.01	Phase 2	[5]
Votucalis	DMW4LTI	Allergic rhinitis	CA08.0	Phase 2	[7]
OX-NLA	DMPEHBJ	Allergic rhinitis	CA08.0	Discontinued in Phase 3	[8]
Tesmilifene	DMPB36I	Breast cancer	2C60-2C65	Discontinued in Phase 2	[9]
CP-118	DMNJD9H	Allergic rhinitis	CA08.0	Discontinued in Phase 2	[10]
REV-598	DM314CZ	Carcinoid syndrome	5B10	Terminated	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42.
5	Clinical pipeline report, company report or official report of e-Therapeutics.
6	LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83.
7	CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils.
8	Clinical pipeline report, company report or official report of Orexo.
9	Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8.
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025139)
11	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819)